创造生物医疗的未来

奥博资本致力于在全球范围内投资世界一流的生物医疗公司,推动创新,解决有待满足的医疗需求,提升患者治疗效果。

量身定制的融资方案和全球团队,帮助创建世界一流的生物医疗公司。

从生物制药到医疗器械、数字健康、诊断和医疗服务,奥博资本致力于在全球范围内寻找能够使人类生活得更健康和更长久的创新项目。

我们深耕全球医疗保健行业投资二十余载:从初创私营公司到大型跨国企业。我们的团队由130余名杰出专业人士组成,其专业背景覆盖科学、医学和投资等领域。奥博资本在全球范围内管理资产逾170亿美元。

我们如何投资

了解我们的医疗创新公司

Messenger RNA targeting to create life-saving therapeutics

ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies.

Learn More

People with cancer can’t wait. Let’s go.

SpringWorks applies a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer.

Learn More

Pushing targeted oncology drug discovery to new heights

Treeline Biosciences is pursuing molecular targets in oncology that are validated but difficult to drug, leveraging its four pillars of drug discovery: mechanistic biology, medicinal chemistry, computational science, and structural biology and protein science.

Learn More

Missing Link in Telehealth

TytoCare is transforming primary care by putting health in the hands of consumers.

Learn More

$17B

资产管理规模达170亿美元

500+

多家投资组合公司

130+

余名专业人士

12

个全球办公室

130+

个 IPO

被投公司

Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking...

Read More link
PortCo (New)

被投公司

Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop...

Read More link
Verona Pharma Logo

被投公司

Verona Pharma Announced FDA approval of Ohtuvayre (ensifentrine) as a maintenance...

Read More link

被投公司

Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking...

Read More link

被投公司

Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop...

Read More link

被投公司

Verona Pharma Announced FDA approval of Ohtuvayre (ensifentrine) as a...

Read More link
img img img img img img img img img